Everything I'd read about practice diagnostics told me the same thing: eventually, you should own the equipment. In practice, I've watched that advice burn through a lot of operating budgets. That's not a knock on the technology—it's a knock on how most of us calculate cost.
I work in quality compliance at Henry Schein. My job is to review spec sheets, sterilization claims, and QC documentation on roughly 200+ products a month before they reach customers. After about 4 years of that, one pattern keeps surfacing: practices decide to buy or outsource based on the unit price, then discover the real costs only after the invoice is signed.
This article is the comparison I walk through with practices when they ask whether to buy their own diagnostic equipment or keep sending samples out. I'll anchor it on the hematology analyzer, because that decision sits right in the middle of the spectrum. And if you're not a lab person, here's the plain-language answer to the question, what is a hematology analyzer? It's a compact instrument that counts and classifies blood cells—red cells, white cells, platelets—and produces results like a complete blood count (CBC) with differential. It's routine, not exotic. In other words, it's the exact spot where the buy-versus-outsource question gets hard.
Here's my comparison framework. Option A: own it. You buy the analyzer, train a staff member, run daily controls, and bill in-house tests. Option B: send it out. You draw the sample, a reference lab runs it, and you pay per test. I'll compare those two paths on four dimensions: real cost per result, quality assurance, workflow, and total lifecycle cost. Each dimension has a winner, and at least one of them will probably surprise you.
1. Real Cost Per Result: The Invoice Is Not the Number That Matters
A reference lab typically charges $8–$25 for a CBC with differential, plus phlebotomy, depending on your region and payer mix. On the ownership side, a mid-range analyzer runs about $10,000–$30,000 (public distributor pricing, early 2025), and reagents cost roughly $1–$3 per sample. Medicare's national limit for a CBC with differential (CPT 85025) is about $11—public data on the CMS Clinical Lab Fee Schedule. That gap between instrument cost and per-test reimbursement is the whole game.
Run the math at 25–40 CBCs per month, and ownership starts to pull ahead. Run it below that, and the reference lab wins. What surprised me the first time I did this analysis for a small practice was how lopsided the cheap end is. The Henry Schein One Step HCG test is a CLIA-waived urine pregnancy cassette that costs roughly $1.50–$2.50 per test in bulk (published catalog pricing, 2025). No analyzer, no warm-up, no daily QC. Sending a patient out for serum hCG instead of using that test is not a cost decision—it's a habit. The in-office version wins that comparison immediately.
The expensive end is where I'm less gentle. I've seen a practice buy a 250-test reagent kit, run 60 samples, and throw the rest away when the kit expired. The price list said $2 per test. The actual cost was $8.33 per usable result. Nobody's quote sheet shows you that number.
2. Quality Assurance: A $25,000 Analyzer Is Not Automatically the Accurate One
This is the dimension where I get the most pushback, and I'll keep pushing. People assume accuracy comes from the price tag. The reality: accuracy comes from your QC discipline. CLIA requires any practice running moderate- or high-complexity tests to run controls at defined intervals, keep a quality manual, and document training. An analyzer doesn't do that for you—a person does.
The reference lab, in fairness, is built around that discipline. They run controls on every shift, participate in proficiency testing, and can show you their accreditation. If I send a CBC out, the biggest risk is pre-analytical: the draw, the storage, the courier. I'd honestly trust a well-run reference lab over a premium analyzer operated by a stressed medical assistant who skipped the control run. That's not a contradiction. Price doesn't create accuracy. Process does. Run the process well, and in-house testing matches the lab's quality while being faster.
From the outside, the premium analyzer looks like the safe choice. From where I sit in quality review, the brand correlates with the invoice, not with the QC log.
Autoclaves are the cleanest example of this. Practices frequently ask which autoclave Henry Schein carries is “the safest.” Honest answer: the safest autoclave is the one whose biological spore test runs weekly and whose cycle logs get reviewed. I've seen a mid-range unit outperform a premium one because the staff followed the protocol. I've also seen the premium one fail because nobody did.
3. Workflow: In-House Is Faster—Until It Isn't
On turnaround time, ownership wins, and it's not close. A CBC result in 12 minutes lets the provider adjust treatment in the same visit. A reference lab result in 24–72 hours means a phone call, a portal message, or a patient who never follows up. For a practice managing chronic disease, same-day results are a clinical advantage, not just patient convenience.
But I've watched in-house workflows stall in ways nobody budgets for. The analyzer requires daily start-up, controls, cleaning cycles, and a named person who's trained and backed up. One practice I know spent 20 minutes troubleshooting a “no results” error, called the service line, and learned their contract didn't cover the reagent delivery system. They owned the equipment. They didn't own the infrastructure.
The dental side of my portfolio runs on the same framework, which is why digital radiography has essentially replaced film. No darkroom, no chemicals, no retakes while the patient waits. According to ADA recommendations on dental radiographs, digital sensors require significantly less radiation than film—the 80–90% reduction figure is widely cited in the dental literature. You also see the image immediately. Once you count retakes and chair time, the comparison isn't even close.
The intraoral scanner is the same story. A physical impression is a send-out: pour it, pack it, ship it, wait days for the lab model. A digital scan captures the same anatomy chairside and uploads in minutes. For a practice doing steady crown and restorative volume, the scanner justifies itself through workflow alone. For a practice doing a handful of preps a month, a $20,000+ scanner is a harder sell—the send-out process still works, and the volume doesn't stress it. Same framework, different conclusion.
4. Total Lifecycle Cost: What the Quote Doesn't Say
This is the section where my job actually earns its keep, because I see the failure modes that hide in price lists. And yes, I've approved my share of orders and then spent the night wondering whether I caught everything. Usually I did. Twice I didn't (ugh, still annoyed about both).
Service contracts are the first hidden line. Industry service plan pricing commonly runs 10–15% of the purchase price per year. On a $15,000 analyzer, that's $4,500–$6,750 over three years, before any parts or labor. The equipment quote never includes it.
Reagents are the bigger trap. Temperature-sensitive kits fail silently. In 2023, a practice called us about an analyzer that kept flagging abnormal results. The reagent fridge had failed over a weekend and nobody documented it. They ran about 80 patient samples on compromised reagents (ugh). Between reference lab redoes and follow-up visits, that mistake cost roughly $2,400. A $400 fridge thermometer would have caught it. I've checked cold-chain documentation on every diagnostic consumable line ever since—including the Henry Schein One Step HCG test, which is a simple product but still heat- and moisture-sensitive. Two lots got rejected this year on exactly that issue (note to self: the system works, even when it's annoying).
On the reference lab side, the hidden costs are quieter: phlebotomy time, courier pickup windows, insurance verification for lab billing, and the patient who was told “we'll call you” and never was. Those costs don't show up on a lab invoice either.
Sterilization equipment belongs in this conversation because an autoclave is the one diagnostic-adjacent purchase nobody should outsource—but almost everyone underprices. The autoclave Henry Schein carries in most practice setups runs from about $3,000 to $12,000 depending on chamber size and whether you need a vacuum cycle for wrapped instruments. When I evaluate an autoclave line, I check serviceability as hard as I check the cycle specs: how fast do replacement parts ship, and is the warranty network national? A low-priced unit with a three-week wait for a heating element isn't a bargain. It's a shutdown. Add those numbers to the quote, and the “cheap” option frequently becomes the expensive one—on both sides of this comparison.
So What Should You Actually Do?
I said I'd give you a conclusion, so here it is, in scenarios.
Send it out if you're running fewer than 15–20 CBCs per week, your test menu is broader than a single analyzer's capacity, or no one on staff can genuinely own the QC program. Capital isn't the only barrier. Discipline is.
Buy the analyzer if your volume is comfortably above the break-even, same-day results actually change care, and you can assign one named person to run QC—not “whoever is working that day.”
For most practices, the smartest move is the middle path: start with the low-risk in-house tests. The Henry Schein One Step HCG test is CLIA-waived, single-use, and cheap enough that the decision doesn't keep anyone up at night. Use it to build a testing habit and track your volume. When the CBC numbers justify it, the analyzer decision makes itself.
And if you're on the dental side, bias toward owning the imaging and scanning tools earlier—the send-out costs are predictable, the workflow gap is large, and the same TCO framework simply lands on a different answer.
After 4 years and a lot of purchase orders, I've come to believe the best choice between buying and outsourcing is the one you can sustain, not the one that looks cheapest on the invoice. The equipment is the entrance fee. The total cost is paid in attention, every day.